Abstract
HANEW, K., SASAKI, A., SATO, S., SHIMIZU, Y., MURAKAMI, O. and YOSHINAGA, K. Foctors Determining the Effectiveness of CB-154 in the Treatment of Acromegaly. Tohoku J. exp. Med., 1983, 139 (1), 91-95 - To predict the effectiveness of CB-154 treatment in patients with acromegaly plasma GH changes induced by CB-154 treatment were compared with GH responses to TRH or arginine tests performed before the treatment. Fourteen patients with active acromegaly (4 males and 10 females, aged 16-68 years) were given 7.5 to 15mg of CB-154 daily for 3 weeks or longer. During the treatment 7 of the 14 cases showed significant GH decreases (20.1 to 86.2%; p<0.05-0.001), and one of the other 7 cases showed a significant GH increase (30.8%;p<0.005) as compared with GH values before the treatment. In the remaining 6 cases no significant GH changes were observed. Before the treatment 12 of the 14 cases showed distinct GH responses (68-7, 033% increase from the basal GH) to the bolus injection of TRH. Ten of these 12 cases also showed an increase in GH to arginine infusion (62-5, 557%). There was a significant relationship between GH changes induced by CB-154 therapy and logarithmic values of the ratio of TRH-induced GH increasevs. arginine-induced GH increase (r=-0.75; p<0.005). Two cases of less responsive type did not show any GH changes to the treatment. It is concluded that CB-154 treatment is effective only in more responsive type of acromegaly, and especially in cases which are more responsive to TRH and less responsive to arginine.
